Our data strongly indicates that CRC cells harboring alterations in KRAS and/or PI3K are sensitive to PI3K p110α inhibition providing an alternative therapeutic approach for KRAS mutant CRC patients who are currently excluded from EGFR-targeted therapies. Here, PIK3CA is linked to colorectal carcinoma.